gefitinib and dinoprostone
gefitinib has been researched along with dinoprostone in 9 studies
Compound Research Comparison
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 29,105 | 1,346 | 6,357 |
Protein Interaction Comparison
Protein | Taxonomy | gefitinib (IC50) | dinoprostone (IC50) |
---|---|---|---|
Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
Research
Studies (9)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
Authors
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
Aasrum, M; Christoffersen, T; Dajani, OF; Guren, TK; Lilleby, P; Meisdalen, K; Sandnes, D; Thoresen, GH; Tveteraas, IH | 1 |
Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
Kim, YM; Park, SY; Pyo, H | 1 |
Hudish, TM; Karoor, V; Keith, RL; Le, M; Miller, YE; Mozer, AB | 1 |
Aasrum, M; Christoffersen, T; Dajani, O; Guren, T; Müller, KM; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
Ciccone, V; Costanza, F; Donnini, S; Morbidelli, L; Terzuoli, E; Ziche, M | 1 |
Beloueche-Babari, M; Delgado-Goñi, T; Galobart, TC; Leach, MO; Normantaite, D; Wantuch, S; Whittaker, SR | 1 |
Other Studies
9 other study(ies) available for gefitinib and dinoprostone
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cells, Cultured; Culture Media, Serum-Free; Cyclin D; Cyclins; Dinoprostone; DNA; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation; Hepatocytes; Liver Neoplasms; Male; Pertussis Toxin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins | 2008 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
Topics: Cyclooxygenase 2; Dinoprostone; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Protein Biosynthesis; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Transcription, Genetic | 2009 |
Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
Topics: Adenoma; Animals; Antineoplastic Agents; Cadherins; Cytochrome P-450 Enzyme System; Dinoprostone; Epoprostenol; ErbB Receptors; Female; Gefitinib; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction | 2010 |
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dinoprostone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction | 2012 |
mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cisplatin; Dinoprostone; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Molecular Targeted Therapy; Prostaglandin-E Synthases; Signal Transduction | 2019 |
Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dinoprostone; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mitochondria; Mutation; Prostaglandin-E Synthases; Proto-Oncogene Proteins B-raf; Pyruvate Carboxylase; Signal Transduction; Skin Neoplasms; Vemurafenib | 2020 |